Electromed (NYSE:ELMD) CFO Bradley Nagel Sells 11,801 Shares

Electromed, Inc. (NYSE:ELMD) CFO Bradley Nagel sold 11,801 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $36.35, for a total transaction of $428,966.35. Following the transaction, the chief financial officer directly owned 19,638 shares in the company, valued at approximately $713,841.30. This represents a 37.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Electromed Stock Performance

ELMD stock opened at $37.08 on Tuesday. Electromed, Inc. has a 52 week low of $17.73 and a 52 week high of $40.00. The firm’s fifty day moving average is $29.79 and its 200 day moving average is $27.87. The firm has a market cap of $307.02 million, a P/E ratio of 49.44 and a beta of 0.53.

Institutional Investors Weigh In On Electromed

Institutional investors and hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in shares of Electromed in the 4th quarter worth about $29,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Electromed in the 4th quarter worth about $43,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Electromed in the 2nd quarter worth about $83,000. New York State Common Retirement Fund purchased a new stake in shares of Electromed in the 2nd quarter worth about $103,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Electromed in the 4th quarter worth about $114,000. 40.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on ELMD shares. Zacks Research raised shares of Electromed from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Roth Mkm reaffirmed a “buy” rating and set a $38.00 target price on shares of Electromed in a report on Wednesday, February 11th. Finally, B. Riley Financial raised their price target on shares of Electromed from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $37.50.

Electromed Company Profile

Electromed Inc (NYSE: ELMD) develops and manufactures sleep therapy products designed to support individuals with breathing disorders such as obstructive sleep apnea. The company’s core business activities include the design, production and distribution of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) accessories. Electromed’s focus on supplying both disposable and reusable components allows durable medical equipment providers to offer comprehensive therapy solutions to patients.

The company’s product portfolio encompasses masks, mask cushions, headgear, tubing, filters and humidification components.